Tumor necrosis factor-alpha: Difference between revisions
Jump to navigation
Jump to search
imported>Howard C. Berkowitz No edit summary |
imported>Howard C. Berkowitz No edit summary |
||
| Line 3: | Line 3: | ||
==Tumor necrosis factor inhibitors== | ==Tumor necrosis factor inhibitors== | ||
* TNFR-Fc fusion protein (etanercept - pronounced et a ner' set) blocks the activity of TNF-alpha.<ref>{{CZMed|Etanercept}}</ref> Etanercept is used for the treatment of autoimmune diseases such as [[ankylosing spondylitis]] and [[ | * TNFR-Fc fusion protein (etanercept - pronounced et a ner' set) blocks the activity of TNF-alpha.<ref>{{CZMed|Etanercept}}</ref> Etanercept is used for the treatment of autoimmune diseases such as [[ankylosing spondylitis]] and [[systemic lupus erythematosus]].<ref name="pmid11986408">{{cite journal |author=Gorman JD, Sack KE, Davis JC |title=Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha |journal=N. Engl. J. Med. |volume=346 |issue=18 |pages=1349–56 |year=2002 |month=May |pmid=11986408 |doi=10.1056/NEJMoa012664 |url=http://content.nejm.org/cgi/content/full/346/18/1349 |issn=}}</ref> | ||
* Infliximab (pronounced in flix' i mab)is a chimeric monoclonal antibody that blocks the action of TNF-alpha by binding to it.<ref>{{CZMed|Infliximab}}</ref> | * Infliximab (pronounced in flix' i mab)is a chimeric monoclonal antibody that blocks the action of TNF-alpha by binding to it.<ref>{{CZMed|Infliximab}}</ref> | ||
Revision as of 20:17, 26 June 2010
In medicine, tumor necrosis factor-alpha is a "serum glycoprotein produced by activated macrophages and other mammalian mononuclear leukocytes. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to tnf-beta (lymphotoxin), but they share TNF receptors.[1]
Tumor necrosis factor inhibitors
- TNFR-Fc fusion protein (etanercept - pronounced et a ner' set) blocks the activity of TNF-alpha.[2] Etanercept is used for the treatment of autoimmune diseases such as ankylosing spondylitis and systemic lupus erythematosus.[3]
- Infliximab (pronounced in flix' i mab)is a chimeric monoclonal antibody that blocks the action of TNF-alpha by binding to it.[4]
Adverse effects
Tumor necrosis factor inhibitors increase susceptibility to serious infections.[5]
References
- ↑ Anonymous (2024), Tumor necrosis factor-alpha (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ The most up-to-date information about Etanercept and other drugs can be found at the following sites.
- Etanercept - FDA approved drug information (drug label) from DailyMed (U.S. National Library of Medicine).
- Etanercept - Drug information for consumers from MedlinePlus (U.S. National Library of Medicine).
- Etanercept - Detailed information from DrugBank.
- ↑ Gorman JD, Sack KE, Davis JC (May 2002). "Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha". N. Engl. J. Med. 346 (18): 1349–56. DOI:10.1056/NEJMoa012664. PMID 11986408. Research Blogging.
- ↑ The most up-to-date information about Infliximab and other drugs can be found at the following sites.
- Infliximab - FDA approved drug information (drug label) from DailyMed (U.S. National Library of Medicine).
- Infliximab - Drug information for consumers from MedlinePlus (U.S. National Library of Medicine).
- Infliximab - Detailed information from DrugBank.
- ↑ Anonymous (2008). FDA MedWatch - 2008 Safety Alerts for Human Medical Products. U.S. Food and Drug Administration.